← All trials
NCT04921111
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 2, 2021
- Primary completion
- Jul 31, 2022
- Completion date
- Oct 31, 2022
- First posted
- Jun 10, 2021
- Last posted
- Sep 17, 2021
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sinocelltech Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.